Bristol-Myers Squibb Company
Patents, Design & Utilities
Last updated:
List of all Bristol-Myers Squibb Company patents 772 in total
| Status | Patent |
|---|---|
Grant | Utility: Cyclic dinucleotides as anticancer agents Filling date: 6 Sep 2025 Issue date: 16 Mar 2021 |
Grant | Utility: Fibronectin based scaffold domain proteins that bind PCSK9 Filling date: 6 Sep 2025 Issue date: 16 Mar 2021 |
Grant | Utility: Methods of purifying proteins Filling date: 6 Sep 2025 Issue date: 16 Mar 2021 |
Application | Utility: FIBRONECTIN TYPE III DOMAIN PROTEINS WITH ENHANCED SOLUBILITY Filling date: 6 Sep 2025 Issue date: 11 Mar 2021 |
Application | Utility: INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE Filling date: 6 Sep 2025 Issue date: 11 Mar 2021 |
Application | Utility: SUBSTITUTED INDOLE ETHER COMPOUNDS Filling date: 6 Sep 2025 Issue date: 11 Mar 2021 |
Grant | Utility: Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor Filling date: 6 Sep 2025 Issue date: 9 Mar 2021 |
Grant | Utility: Carbohydrate content of CTLA4 molecules Filling date: 6 Sep 2025 Issue date: 9 Mar 2021 |
Application | Utility: METHODS AND COMPOSITIONS FOR DEUTERATED BIOLOGICS Filling date: 6 Sep 2025 Issue date: 4 Mar 2021 |
Application | Utility: SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS Filling date: 6 Sep 2025 Issue date: 4 Mar 2021 |
Grant | Utility: Serum albumin binding molecules Filling date: 6 Sep 2025 Issue date: 2 Mar 2021 |
Grant | Utility: Heterocyclic sulfones as ROR gamma modulators Filling date: 6 Sep 2025 Issue date: 2 Mar 2021 |
Application | Utility: ANTIBODIES TO CD40 Filling date: 6 Sep 2025 Issue date: 25 Feb 2021 |
Application | Utility: ANTAGONISTIC CD40 MONOCLONAL ANTIBODIES AND USES THEREOF Filling date: 6 Sep 2025 Issue date: 25 Feb 2021 |
Application | Utility: USE OF CAPRYLIC ACID PRECIPITATION FOR PROTEIN PURIFICATION Filling date: 6 Sep 2025 Issue date: 25 Feb 2021 |
Application | Utility: MACROCYCLIC TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS Filling date: 6 Sep 2025 Issue date: 25 Feb 2021 |
Application | Utility: COMPOUNDS USEFUL AS IMMUNOMODULATORS Filling date: 6 Sep 2025 Issue date: 25 Feb 2021 |
Application | Utility: COMBINATION THERAPY WITH ANTI-IL-8 ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TREATING CANCER Filling date: 6 Sep 2025 Issue date: 25 Feb 2021 |
Grant | Utility: Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor Filling date: 6 Sep 2025 Issue date: 23 Feb 2021 |
Grant | Utility: Immunotherapeutic dosing regimens comprising pomalidomide and an anti-CS1 antibody for treating cancer Filling date: 6 Sep 2025 Issue date: 23 Feb 2021 |
Application | Utility: COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE Filling date: 6 Sep 2025 Issue date: 18 Feb 2021 |
Grant | Utility: Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor Filling date: 6 Sep 2025 Issue date: 16 Feb 2021 |
Grant | Utility: Compositions monovalent for CD28 binding and methods of use Filling date: 6 Sep 2025 Issue date: 16 Feb 2021 |
Application | Utility: TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR Filling date: 6 Sep 2025 Issue date: 11 Feb 2021 |
Grant | Utility: Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor Filling date: 6 Sep 2025 Issue date: 9 Feb 2021 |
Grant | Utility: [1,2,4]triazolo[1,5-A]pyridinyl substituted indole compounds Filling date: 6 Sep 2025 Issue date: 9 Feb 2021 |
Grant | Utility: Aminotriazolopyridines as kinase inhibitors Filling date: 6 Sep 2025 Issue date: 9 Feb 2021 |
Application | Utility: METHODS OF TREATING TUMOR Filling date: 6 Sep 2025 Issue date: 4 Feb 2021 |
Application | Utility: HETEROCYCLIC COMPOUNDS COMPRISING PYRIDINE USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES Filling date: 6 Sep 2025 Issue date: 4 Feb 2021 |
Application | Utility: COMPOSITIONS AND METHODS OF TREATING CANCER Filling date: 6 Sep 2025 Issue date: 4 Feb 2021 |
Grant | Utility: Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazines as factor xia inhibitors Filling date: 6 Sep 2025 Issue date: 2 Feb 2021 |
Application | Utility: REAL-TIME MONITORING OF PROTEIN CONCENTRATION USING ULTRAVIOLET SIGNAL Filling date: 6 Sep 2025 Issue date: 28 Jan 2021 |
Application | Utility: METHOD OF PURITY DETERMINATION BY CAPILLARY ELECTROPHORESIS Filling date: 6 Sep 2025 Issue date: 28 Jan 2021 |
Grant | Utility: Substituted glycine derived FXIA inhibitors Filling date: 6 Sep 2025 Issue date: 26 Jan 2021 |
Grant | Utility: Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making Filling date: 6 Sep 2025 Issue date: 26 Jan 2021 |
Grant | Utility: Anti-ICOS agonist antibodies and uses thereof Filling date: 6 Sep 2025 Issue date: 26 Jan 2021 |
Grant | Utility: Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phe- nyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide Filling date: 6 Sep 2025 Issue date: 26 Jan 2021 |
Grant | Utility: Methods for maintaining pegylation of polypeptides Filling date: 6 Sep 2025 Issue date: 26 Jan 2021 |
Application | Utility: MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS Filling date: 6 Sep 2025 Issue date: 21 Jan 2021 |
Application | Utility: Combination of Anti-LAG-3 Antibodies and Anti-PD-1 Antibodies to Treat Tumors Filling date: 6 Sep 2025 Issue date: 14 Jan 2021 |
Application | Utility: ANTI-GITR ANTIBODIES FOR CANCER DIAGNOSTICS Filling date: 6 Sep 2025 Issue date: 14 Jan 2021 |
Application | Utility: METHODS OF PURIFYING MONOMERIC MONOCLONAL ANTIBODIES Filling date: 6 Sep 2025 Issue date: 14 Jan 2021 |
Application | Utility: METABOLIC ENZYME ACTIVITY AND DISULFIDE BOND REDUCTION DURING PROTEIN PRODUCTION Filling date: 6 Sep 2025 Issue date: 14 Jan 2021 |
Grant | Utility: Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents Filling date: 6 Sep 2025 Issue date: 12 Jan 2021 |
Grant | Utility: 4-hydroxy-3-sulfonylpyridin-2(1H)-ones as APJ receptor agonists Filling date: 6 Sep 2025 Issue date: 12 Jan 2021 |
Application | Utility: USE OF IMMUNE CHECKPOINT INHIBITORS IN CENTRAL NERVOUS SYSTEMS NEOPLASMS Filling date: 6 Sep 2025 Issue date: 7 Jan 2021 |
Application | Utility: CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS Filling date: 6 Sep 2025 Issue date: 7 Jan 2021 |
Grant | Utility: Compounds useful as immunomodulators Filling date: 6 Sep 2025 Issue date: 5 Jan 2021 |
Application | Utility: COMBINATION OF A TETANUS TOXOID, ANTI-OX40 ANTIBODY AND/OR ANTI-PD-1 ANTIBODY TO TREAT TUMORS Filling date: 6 Sep 2025 Issue date: 31 Dec 2020 |
Grant | Utility: Process for preparing tetrahydrocarbazole carboxamide compound Filling date: 6 Sep 2025 Issue date: 29 Dec 2020 |
Showing 350 to 400 of 772 patents.